ZOM Zomedica Corp

Dr. Morley, age 44, joined the initial management team of the Company shortly after its founding. Dr. Morley has over 15 years of experience as a life science executive and practicing veterinarian with a broad career in operations, business development and clinical veterinary practice. After practicing small animal medicine and surgery in New Mexico and Michigan, she took on expanding leadership roles at MPI Research and University of Michigan Medical School Fast Forward Medical Innovation. In her expanded role, Dr. Morley will be responsible for all operational functions of the Company.

In connection with her appointment as President, Dr. Morley entered into a new employment agreement, dated September 16, 2019 (the “Employment Agreement”), with the Company’s wholly-owned subsidiary, Zomedica Pharmaceuticals Inc., a copy of which is filed herewith as Exhibit 10.30. The Employment Agreement has an initial term of three years and automatically extends for one-year terms unless either party elects to terminate it. Under the Employment Agreement, Dr. Morley will receive an annual base salary of $225,000, subject to annual review, and will be entitled to quarterly cash bonuses upon the achievement of certain specified objectives established by the Board. Pursuant to the Employment Agreement, Dr. Morley will receive a $2,000 monthly allowance in respect of the following items: (i) vehicle and (ii) tax preparation, and is entitled to four weeks paid vacation time. Pursuant to the Employment Agreement, any options granted to Dr. Morley will be subject to accelerated vesting in the event that Dr. Morley’s employment is terminated by the Company without cause. The Employment Agreement also includes customary non-solicitation, confidentiality and assignment of inventions provisions. In the event that Dr. Morley has a “separation from service” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended, Dr. Morley would have the right to exercise all of her options, and the Company would be required to pay her a lump sum equal to 12 months of her base salary and any quarterly bonus allocable or payable prior to the date of termination.

The Board also granted to Dr. Morley stock options to acquire up to an aggregate of 500,000 common shares of the Company pursuant to the Company’s stock option plan. All of the stock options vested immediately upon the date of grant and are exercisable for a period of two years at a price of US$0.43 per common share.

There are no family relationships between Dr. Morley and any director or executive officer of the Company, and she has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.